Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

September 10, 2019 updated by: Britta Hahn, University of Maryland, Baltimore

Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by currently available medications. Cognitive training improves these functions to some degree, but this approach is time- and resource-intensive. The current project aims at enhancing and accelerating the benefits that people with schizophrenia derive from cognitive training by administering nicotine during some of the training sessions. This would provide the proof of principle for a type of treatment intervention to improve cognitive symptoms of schizophrenia.

The current project aims at determining whether the intermittent presence of nicotine during cognitive training exercises in people with schizophrenia will shorten the training period necessary to induce significant and clinically relevant improvement and enhance the improvement seen after a training period of specified length.

Hypothesis 1a: Nicotine administration during training will increase the size of all measured effects of the training intervention, and will accelerate the time course of performance enhancement on the MCCB and training exercise progression parameters.

Hypothesis 1b: The larger training effects in the Nicotine Group will persist beyond the end of the intervention.

Hypothesis 2a: Within-session progress on the training exercises will be larger in the presence of nicotine than in the presence of placebo.

Hypothesis 2b: These acute nicotine-induced performance elevations will persist beyond the presence of nicotine through subsequent non-drug training sessions, giving evidence of an acute facilitation of learning processes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maryland
      • Baltimore, Maryland, United States, 21228
        • Maryland Psychiatric Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18-60 years.
  • DSM diagnosis of schizophrenia or schizoaffective disorder.
  • Ability to give written informed consent.
  • Either currently smoking and not attempting to quit, or having smoked no more than 80 cigarettes, cigarillos or cigars in lifetime and not at all within the last year.
  • Normal or corrected to normal vision (at least 20/50).
  • Four weeks of stable pharmacological treatment (same psychiatric medication at same dose) and no foreseeable changes at enrollment.

Exclusion Criteria:

  • Alcohol or substance abuse or dependence other than nicotine within the last 12 months.
  • Uncontrolled hypertension (resting systolic blood pressure above 150 or diastolic above 90 mm Hg).
  • History of myocardial infarction, heart failure, angina, stroke or severe arrhythmias.
  • ECG abnormalities.
  • History of neurological conditions such as stroke, seizures, dementia or organic brain syndrome.
  • Mental retardation.
  • Pregnant, verified by urine pregnancy test for females.
  • Breast-feeding.
  • Treated with benztropine currently or within the last four weeks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Cognitive remediation training with nicotine
Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Behavioral: Cognitive remediation training
Other Names:
  • Posit Science cognitive remediation training
Drug: Nicotine polacrilex lozenge
Of interest are the effects of nicotine on cognitive remediation training benefits.
Other Names:
  • Nicorette polacrilex lozenges, GlaxoSmithKline, 2 mg and 4 mg
Placebo Comparator: Cognitive remediation training without nicotine
Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
Behavioral: Cognitive remediation training
Other Names:
  • Posit Science cognitive remediation training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MATRICS Consensus Cognitive Battery (MCCB) Composite Score
Time Frame: baseline (week 0), weeks 4 and 7 of intervention, end-of-intervention (week 10), 4-week follow-up
The MCCB is an FDA-approved assessment tool for trials of cognition-enhancing treatments in people with schizophrenia. The MCCB is comprised of the following domains: 1) Speed of Processing; 2) Attention/Vigilance; 3) Working Memory; 4) Verbal Learning; 5) Visual Learning; 6) Reasoning and Problem Solving; and 7) Social Cognition. The composite score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Better performance is reflected by higher scores.
baseline (week 0), weeks 4 and 7 of intervention, end-of-intervention (week 10), 4-week follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive Assessment Interview (CAI) Score
Time Frame: baseline (week 0) and post-intervention (week 10)
Clinician-administered interview about daily life cognitive functioning. The CAI assesses 10 items related to working memory, attention/vigilance, learning/memory, problem solving, processing speed, and social cognition. The total score ranges from 1 (inability to maintain personal hygiene due to cognitive deficits) to 100 (superior cognitive functioning in a wide range of activities). A score of 55 corresponds to moderate cognitive symptoms, e.g. persistent problems paying attention or forgetting scheduled events.
baseline (week 0) and post-intervention (week 10)
Change in Abbreviated Schizophrenia Quality of Life Scale Score
Time Frame: baseline (week 0) and post-intervention (week 10)
Semi-structured clinician interview measuring functional outcome and quality of life in people with schizophrenia. Includes subjective questions regarding life satisfaction and objective indicators of social and occupational role functioning during preceding 4 weeks. Seven items are scored on a 0 (severe impairment) to 6 (high functioning) scale. The total score ranges from 0 to 42, with larger values reflecting higher functioning.
baseline (week 0) and post-intervention (week 10)
UCSD Performance-Based Skills Assessment (UPSA) Score
Time Frame: baseline (week 0) and post-intervention (week 10)
Measures ability to perform real-life tasks by standardized role-play. Scores reflect percent correct, i.e. range from 0-100 with higher scores representing better performance.
baseline (week 0) and post-intervention (week 10)
Calgary Depression Scale Score
Time Frame: baseline (week 0), post-intervention (week 10)
Clinician scale developed to assess the level of depression in schizophrenia. 9 items assess symptoms of depression and overall rater impression on a scale from 0 (absent) to 3 (severe).
baseline (week 0), post-intervention (week 10)
Scale for the Assessment of Negative Symptoms (SANS) Score
Time Frame: baseline (week 0), post-intervention (week 10)
Clinician rating scale of negative symptoms in schizophrenia. Within each of 5 domains, separate symptoms are rated from 0 (absent) to 5 (severe). Total scores are the sum of 22 subscales and range from 0 to 110, with larger values reflecting higher negative symptoms.
baseline (week 0), post-intervention (week 10)
Brief Psychiatric Rating Scale (BPRS) Score
Time Frame: baseline (week 0), post-intervention (week 10)
Clinician rating scale to measure psychotic symptoms. Each of 20 items is scored 1-7. Total scores are the sum of all items and range from 20 to 140, with larger values reflecting worse symptoms.
baseline (week 0), post-intervention (week 10)
Training Exercise Parameters: Visual and Sound Sweeps
Time Frame: baseline (week 0), post-intervention (week 10), 4-week follow-up
Some of the Posit Science exercises provide an assessment tool of training progress on task parameters, which adjust continuously to keep performance at ~85% correct. Enhanced sensory processing speed and precision is considered the central building block of training benefits. Therefore, we analyzed the two exercises aimed at training these processes. Performance is quantified as stimulus presentation time in ms of visual or sound "sweeps", which the participant has to judge in terms of change across space or time. Smaller values reflect better performance. Visual and sound sweeps were averaged.
baseline (week 0), post-intervention (week 10), 4-week follow-up
Change in Working Memory Capacity
Time Frame: baseline (week 1) and post-intervention (week 10)
Derived from a computerized change localization task. One to four colored squares are shown for 100 ms. After a delay, they reappear and the task is to click on the one square that has changed color (50% chance). Performance is expressed as the percentage of correct responses.
baseline (week 1) and post-intervention (week 10)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Maryland, Baltimore

Collaborators

National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Britta Hahn, Ph.D., University of Maryland School of Medicine, Maryland Psychiatric Research Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

June 1, 2017

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

February 5, 2014

First Submitted That Met QC Criteria

February 21, 2014

First Posted (Estimate)

February 24, 2014

Study Record Updates

Last Update Posted (Actual)

September 12, 2019

Last Update Submitted That Met QC Criteria

September 10, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HP-00058233
  • R21MH095824 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Cognitive remediation training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe